Schrodinger Inc. announced a strategic shift to move 75% of its software contracts to hosted cloud models within three years to meet increasing customer demand for cloud-integrated solutions. The company is collaborating with AI developers like Anthropic and partners such as Eli Lilly to enhance its AI-powered drug discovery tools. Despite a slight revenue decline, Schrodinger surpassed analyst expectations in Q4 2025, driven by a significant increase in drug discovery revenue.

Sallie Mae (Nasdaq: SLM) announced it will release its first-quarter 2026 financial results after market close on Thursday, April 23. The company will host a live audio webcast and presentation slides on its investor relations website at 5:30 p.m. ET on the same day. Investors can find the earnings release and webcast details on Sallie Mae's investor relations website.

JPMorgan Chase & Co. and its affiliates have announced they are no longer a substantial shareholder in DUG Technology Ltd, effective April 15, 2026. This change resulted from transactions including rehypothecation of client securities under a prime brokerage agreement and principal trading by J.P. Morgan Securities entities. The administrative notice indicates a shift in DUG Technology's institutional investor base, which could be monitored by investors for potential impacts on liquidity and support, though it does not directly affect the company's operations.

The iShares iBoxx $ High Yield Corporate Bond ETF (HYG) continues to provide stable monthly distributions to investors, ranging from $0.36 to $0.41 per share, supported by a resilient macroeconomic environment including a 4.3% unemployment rate. This stability is maintained despite Federal Reserve interest rate cuts, which have helped mitigate refinancing pressures for leveraged companies within the ETF's portfolio. With a market capitalization nearing $18 billion, HYG remains a significant bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index and offering consistent income while its shares have gained nearly 10% in value over the past year.

News Corporation has cancelled 201,601 ASX-listed Class B shares through a buy-back, effective April 17, 2026. This move slightly reduces the company's issued capital, signaling active capital management aimed at enhancing shareholder value. An analyst has rated AU:NWS stock a "Buy" with a A$50.00 price target.

This article provides a stock forecast and analyst predictions for Skillsoft (NYSE:SKIL). It notes a lack of sufficient analyst coverage to forecast immediate growth and revenue, yet details numerous past and projected earnings and revenue guidance updates. The report also includes financial data from analysts forecasting revenue, earnings, free cash flow, and cash from operations through early 2027.

Google's 2026 Discover Core Update, completed on February 27, 2026, is profoundly changing how investors access news about Leidos Holdings Inc (LDOS). The update decouples Discover from traditional search, prioritizing personalized mobile feeds based on user activity, location, and content engagement. This shift provides investors with earlier access to critical developments concerning Leidos' defense contracts, cybersecurity advancements, and national security tech trends, offering a real-time edge in tracking the stock's performance.

Despite a recent dip of over 20% from its October 2025 all-time high, Microsoft's stock presents a compelling long-term buying opportunity. The company is well-positioned to navigate the AI revolution by integrating AI into its products, and its business model with a significant portion of recurring revenue and strong financials makes it resilient to economic downturns. Furthermore, even with its recent recovery, Microsoft's shares are considered reasonably valued compared to its Magnificent Seven peers, making it an attractive investment for the long term.

This article provides financial information for Prestige Consumer Healthcare Inc. (FWB:PBV) listed on the Frankfurt Stock Exchange, specifically focusing on its revenue per share. It mentions market data from ICE Data Services and reference data from FactSet. The content indicates that the market is currently closed

Pacific Biosciences of California (PacBio) is advancing cancer drug research and development by introducing its HiFi sequencing technology, which offers a unified view of structural variants and isoforms often missed by traditional methods. This technology aims to accelerate innovation in cancer therapeutics. Additionally, PacBio launched its SMRT Grant program to support researchers utilizing its sequencing solutions in oncology.